About 15% of people using injectable GLP-1 drugs like Ozempic and Wegovy are experimenting with "microdosing," or taking smaller-than-prescribed doses, according to a 2026 survey by health-tech company Evidation Health. While cost savings drive some of this trend, a surprising 41% of microdosers say they're trying to manage side effects like nausea and fatigue. The problem: doctors have almost no data on whether this approach actually works or if it's safe.

Why Are People Taking Smaller Doses of GLP-1 Drugs?

The reasons people microdose fall into several categories, and doctors view some more favorably than others. Cost remains a major factor. A month's supply of Zepbound purchased directly from its maker, Eli Lilly and Company, can cost $299 to $449, while Ozempic and Wegovy carry comparable list prices, and insurance coverage remains inconsistent.

But the financial motivation tells only part of the story. Many users experience uncomfortable side effects when taking standard doses, particularly when doses are increased. In a large randomized clinical trial published in The Lancet, people taking 1 milligram of semaglutide (the active ingredient in Ozempic and Wegovy) experienced fewer adverse effects than those taking the higher 2.4-milligram dose.

Some people also adjust their dosing schedule in hopes of making side effects more manageable. Others use microdosing as a weight-maintenance strategy after reaching their goal weight, wondering if they can keep results with less medication. Nearly 30% of microdosers surveyed said they were taking less medication specifically for weight maintenance.

What Exactly Counts as "Microdosing"?

The term "microdosing" is social media shorthand for what doctors call alternative dosing, off-label dosing, or dose reduction. These approaches aren't all identical, and understanding the differences matters. According to Dr. Betul Hatipoglu, director of the Center for Diabetes, Obesity and Metabolism at Case Western Reserve University, microdosing might involve:

Dr. Betul Hatipoglu

• Lower total dose: Taking a smaller amount than what was prescribed or studied in clinical trials
• Split dosing: Taking a half-dose every few days instead of a full dose once weekly
• Extended intervals: Taking a full dose less often, such as every 10 or 14 days instead of every seven

Some of these approaches reduce the total amount of medication taken, while others simply change the frequency. The distinction matters because the effects on your body may differ depending on which strategy you choose.

Does Microdosing Actually Work for Weight Loss?

Here's the uncomfortable truth: we don't know. The doses approved by the U.S. Food and Drug Administration (FDA) for Ozempic, Wegovy, Zepbound, and Mounjaro were extensively studied in large clinical trials and shown to be effective for weight loss. Microdosing strategies were not.

The Access and Policy Working Group of the Obesity Medicine Association, the largest U.S. professional society of clinicians specializing in obesity care, states there is currently "little to no peer-reviewed evidence" supporting the safety or effectiveness of microdosed regimens for obesity.

"We just don't have a lot of data or trials. There seems to be a broad range of sensitivity to the medications among different people," said Dr. Richard Siegel, co-director of the Diabetes and Lipid Center at Tufts Medical Center in Boston.

Dr. Richard Siegel, Co-Director of the Diabetes and Lipid Center at Tufts Medical Center

That said, doctors acknowledge that lower doses may still help some people. A 2025 commentary in Diabetes Care suggested that individualized dosing approaches may help some patients remain on treatment when standard dosing isn't ideal. Obesity specialists routinely see patients respond differently to GLP-1 drugs, and some appear to achieve meaningful weight loss on lower doses than others.

The catch: results may be slower, less predictable, or insufficient compared with the regimens that have actually been studied. You might lose weight on a microdose, but you might not, and there's no way to know in advance which outcome applies to you.

How to Discuss Dosing Changes With Your Doctor

• Be honest about side effects: Tell your doctor specifically which side effects you're experiencing, when they occur, and how severe they are. This information helps them decide whether dose adjustment is appropriate for you
• Discuss financial barriers: If cost is preventing you from taking the full dose, mention this to your doctor. They may know about patient assistance programs, generic alternatives, or other resources you haven't considered
• Avoid self-adjusting: Don't change your dose on your own without medical guidance. Even though microdosing happens outside clinical trial protocols, your doctor can help you make informed decisions about any changes
• Ask about maintenance dosing: If you've reached your goal weight, ask your doctor whether a lower maintenance dose might be appropriate for you, as this is different from unsupervised microdosing

What Are the Safety Risks of Microdosing?

Reducing the dose may help with common side effects like nausea and vomiting, but it doesn't necessarily eliminate the medications' risks. That's because "GLP-1 risks are generally not dose dependent," according to Dr. Hatipoglu.

Dr. Hatipoglu

Though rare, those risks include allergic reactions, low blood sugar, and pancreatic or kidney problems. These serious complications can occur regardless of whether you're taking a full dose or a microdose.

There's also a concerning trend that worries obesity specialists. Some people at a healthy weight, without diabetes or related health conditions, are becoming interested in microdosing because they believe the medication might protect their heart, kidneys, liver, and other organs. Dr. Hatipoglu emphasized the problem with this approach: "My answer to that is no. We have no clue how you'll respond or whether it's safe".

Dr. Hatipoglu

The rise of telemedicine clinics has made it easier to access GLP-1 medications, even for people who may not meet the criteria for their use. Influencers often tout microdosing as a way to lose "those last 10 pounds," despite the fact that GLP-1 drugs are approved for people with obesity or those who are overweight and have related health conditions.

The bottom line: while the cost and side effect burden of GLP-1 drugs are real concerns, microdosing remains an unproven strategy with unclear risks. If you're considering adjusting your dose, talk to your doctor first rather than experimenting on your own.